Table 1 Study participant characteristics.
Characteristic | Intubated (n = 92) | Non-intubated (n = 102) | P value |
|---|---|---|---|
Age, median (IQR) | 61 (53, 70) | 59 (42, 67) | 0.175 |
Gender | 0.349 | ||
Female | 31 (34%) | 41 (40%) | |
Male | 61 (66%) | 61 (60%) | |
Patient race | 0.316 | ||
Asian | 40 (43%) | 35 (34%) | |
Black or African American | 0 (0%) | 1 (1%) | |
Native Hawaiian or Other Pacific Islander | 41 (45%) | 46 (45%) | |
White-Non-Hispanic | 11 (12%) | 18 (18%) | |
White Hispanic | 0 (0%) | 2 (2%) | |
BMI ≥ 30 | 58 (63%) | 61 (60%) | 0.644 |
Length of stay in hospital | 12 (9, 15) | 22 (14, 26) | < 0.001 |
Days on HFNC | 1.7 (0.9, 1.3) | 4.7 (3.8. 6.2) | < 0.001 |
Symptoms until HFNC days | 8 (7, 12) | 10 (7, 12) | 0.805 |
Hypertension | 67 (73%) | 58 (57%) | 0.020 |
Secondary pneumonia | 12 (13%) | 26 (25%) | 0.029 |
Acute kidney injury | 37 (40%) | 35 (34%) | 0.395 |
Cancer not in remission | 7 (8%) | 6 (6%) | 0.631 |
Ischemic heart disease | 15 (16%) | 17 (17%) | 0.946 |
Congestive heart failure | 15 (16%) | 16 (16%) | 0.907 |
Chronic pulmonary disease | 8 (9%) | 8 (8%) | 0.829 |
Asthma | 11 (12%) | 13 (13%) | 0.868 |
Active smoker | 10 (11%) | 10 (10%) | 0.807 |
Diabetes | 48 (52%) | 46 (45%) | 0.325 |
Immunocompromised | 11 (12%) | 10 (10%) | 0.630 |
Hepatic failure | 7 (8%) | 3 (3%) | 0.196 |
End stage renal disease | 6 (7%) | 2 (2%) | 0.153 |
Chronic kidney disease | 23 (25%) | 19 (19%) | 0.282 |
Vaccinated against COVID-19 | 17 (18%) | 21 (21%) | 0.712 |
Taking remdesivir | 70 (76%) | 87 (85%) | 0.103 |
Taking dexamethasone | 92 (100%) | 102 (100%) | 1.000 |
Expired | 48 (52%) | 0 (0%) | < 0.001 |
